{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:28:47Z","timestamp":1792535327754,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jjcc.2020.12.013","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T08:18:07Z","timestamp":1609316287000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":355,"title":["Uric acid and cardiovascular disease: A clinical review"],"prefix":"10.1016","volume":"78","author":[{"given":"Yuichi","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2020.12.013_bib0001","doi-asserted-by":"crossref","first-page":"k3951","DOI":"10.1136\/bmj.k3951","article-title":"Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts","volume":"363","author":"Major","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0002","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0003","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jare.2017.03.003","article-title":"Physiological functions and pathogenic potential of uric acid: a review","volume":"8","author":"El Ridi","year":"2017","journal-title":"J Adv Res"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0004","doi-asserted-by":"crossref","first-page":"E827","DOI":"10.1152\/ajpendo.00378.2020","article-title":"New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity","volume":"319","author":"Furuhashi","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0005","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0006","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.atherosclerosis.2018.10.007","article-title":"Hyperuricemia and endothelial function: from molecular background to clinical perspectives","volume":"278","author":"Maruhashi","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0007","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1042\/bj2350747","article-title":"Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid","volume":"235","author":"Davies","year":"1986","journal-title":"Biochem J"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0008","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1681\/ASN.2005050572","article-title":"Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells","volume":"16","author":"Kang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0009","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jare.2016.11.004","article-title":"Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review","volume":"8","author":"Sharaf El Din","year":"2017","journal-title":"J Adv Res"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0010","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.amjcard.2004.06.032","article-title":"Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk","volume":"94","author":"Mercuro","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0011","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/HYPERTENSIONAHA.116.08436","article-title":"Uric acid is associated with inflammation, coronary microvascular dysfunction, and adverse outcomes in postmenopausal women","volume":"69","author":"Prasad","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0012","doi-asserted-by":"crossref","first-page":"362","DOI":"10.5551\/jat.45179","article-title":"Relation of elevated serum uric acid level to endothelial dysfunction in patients with acute coronary syndrome","volume":"26","author":"Saito","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0013","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ijcard.2018.06.017","article-title":"Cross-sectional and longitudinal associations between serum uric acid and endothelial function in subjects with treated hypertension","volume":"272","author":"Tanaka","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0014","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","article-title":"Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study","volume":"131","author":"Culleton","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0015","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","article-title":"Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study","volume":"164","author":"Niskanen","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0016","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","article-title":"Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National health and nutrition examination survey","volume":"283","author":"Fang","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0017","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/01.HYP.36.6.1072","article-title":"Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study","volume":"36","author":"Verdecchia","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0018","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.STR.29.3.635","article-title":"Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus","volume":"29","author":"Lehto","year":"1998","journal-title":"Stroke"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0019","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.amjcard.2019.09.004","article-title":"Impact of elevated serum uric acid level on target lesion revascularization after percutaneous coronary intervention for chronic total occlusion","volume":"124","author":"Okuya","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.amjcard.2005.04.007","article-title":"Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese acute coronary syndrome study)","volume":"96","author":"Kojima","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0021","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0022","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/01.HYP.0000091371.53502.D3","article-title":"Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation","volume":"42","author":"Masuo","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/01.HYP.0000150783.79172.bb","article-title":"Childhood uric acid predicts adult blood pressure: the Bogalusa heart study","volume":"45","author":"Alper","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0024","article-title":"Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0025","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","article-title":"Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia","volume":"23","author":"Sanchez-Lozada","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0026","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","article-title":"Uric acid reduction rectifies prehypertension in obese adolescents","volume":"60","author":"Soletsky","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0027","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/heartjnl-2014-305683","article-title":"Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial","volume":"100","author":"Higgins","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003095","article-title":"Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: a randomized, controlled trial","volume":"17","author":"Tanaka","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jash.2015.05.009","article-title":"The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic","volume":"9","author":"Segal","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0030","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10157-018-1530-1","article-title":"Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)","volume":"22","author":"Wada","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0031","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with Stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0032","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0033","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0034","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1253\/circj.CJ-16-0766","article-title":"Uric acid level and prevalence of atrial fibrillation in a Japanese general population of 285,882","volume":"80","author":"Kawasoe","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0035","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.hrthm.2014.04.003","article-title":"Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis","volume":"11","author":"Tamariz","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0036","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/j.1540-8167.2012.02356.x","article-title":"Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction","volume":"23","author":"Sakabe","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0037","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/ndt\/gft029","article-title":"Uric acid and chronic kidney disease: which is chasing which?","volume":"28","author":"Johnson","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0038","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ndt\/gfu352","article-title":"Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German chronic kidney disease (GCKD) study","volume":"30","author":"Jing","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0039","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","article-title":"Association of uric acid with change in kidney function in healthy normotensive individuals","volume":"56","author":"Bellomo","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12882-018-1143-7","article-title":"Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis","volume":"20","author":"Luo","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0041","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-93-6-817","article-title":"Serum uric acid in essential hypertension: an indicator of renal vascular involvement","volume":"93","author":"Messerli","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0042","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijcard.2010.05.002","article-title":"Hyperuricemia predicts adverse outcomes in patients with heart failure","volume":"151","author":"Hamaguchi","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0043","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCHEARTFAILURE.108.797662","article-title":"Hyperuricemia and incident heart failure","volume":"2","author":"Krishnan","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0044","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40885-020-00146-y","article-title":"Uric acid and cardiometabolic diseases","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0046","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.cardfail.2008.06.006","article-title":"Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice","volume":"14","author":"Xu","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0047","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","article-title":"Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies","volume":"105","author":"Doehner","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0048","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.CIR.0000022140.61460.1D","article-title":"Allopurinol improves endothelial dysfunction in chronic heart failure","volume":"106","author":"Farquharson","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0049","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","article-title":"High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid","volume":"114","author":"George","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0050","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0051","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) Study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0052","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.STR.0000221716.55088.d4","article-title":"Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study","volume":"37","author":"Bos","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0053","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12872-016-0379-z","article-title":"Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies","volume":"16","author":"Zuo","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12928-019-00625-6","article-title":"Clinical expert consensus document on standards for measurements and assessment of intravascular ultrasound from the Japanese association of cardiovascular intervention and therapeutics","volume":"35","author":"Saito","year":"2020","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0055","article-title":"Contemporary coronary drug-eluting and coated stents: a mini-review","author":"Saito","year":"2020","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0056","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.amjcard.2015.07.059","article-title":"Relation of lipid content of coronary plaque to level of serum uric acid","volume":"116","author":"Saito","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0057","doi-asserted-by":"crossref","first-page":"932","DOI":"10.5551\/jat.33951","article-title":"Impact of serum uric acid levels on coronary plaque stability evaluated using integrated backscatter intravascular ultrasound in patients with coronary artery disease","volume":"23","author":"Ando","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0058","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjcard.2019.12.043","article-title":"Relation of plasma xanthine oxidoreductase activity to coronary lipid core plaques assessed by near-infrared spectroscopy intravascular ultrasound in patients with stable coronary artery disease","volume":"125","author":"Mori","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0059","article-title":"Greater coronary lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound in patients with elevated xanthine oxidoreductase: a mechanistic insight","author":"Saito","year":"2020","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/MCA.0000000000000874","article-title":"Systemic endothelial dysfunction in patients with vasospastic and microvascular angina: serum uric acid as a marker of reactive hyperemia index","volume":"31","author":"Saito","year":"2020","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00380-018-1207-4","article-title":"Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm","volume":"34","author":"Watanabe","year":"2019","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0062","article-title":"Role of acetylcholine spasm provocation test as a pathophysiological assessment in nonobstructive coronary artery disease","author":"Suzuki","year":"2020","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0063","doi-asserted-by":"crossref","first-page":"j2376","DOI":"10.1136\/bmj.j2376","article-title":"Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies","volume":"357","author":"Li","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0064","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0065","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1681\/ASN.2014070660","article-title":"Uric acid and cardiovascular events: a Mendelian randomization study","volume":"26","author":"Kleber","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0066","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-8587(15)00386-1","article-title":"Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis","volume":"4","author":"White","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0067","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002937","article-title":"Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: a phenome-wide Mendelian randomization study","volume":"16","author":"Li","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0068","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-015-0047-z","article-title":"Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis","volume":"16","author":"Kanji","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0069","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0070","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0071","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2020.12.013_bib0072","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","article-title":"Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial","volume":"375","author":"Noman","year":"2010","journal-title":"Lancet"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508720304159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508720304159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:04:42Z","timestamp":1760274282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508720304159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0914508720304159"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2020.12.013","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uric acid and cardiovascular disease: A clinical review","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2020.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}